MAP
NVCR icon

Moody Aldrich Partners’s NovoCure NVCR Stock Holding History

Moody Aldrich Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-30,682
Closed -$2.07M – 181
2020
Q1 		$2.07M Sell
30,682
-69
-0.2% -$5.45K 0.62% 68
2019
Q4 		$2.59M Buy
30,751
+885
+3% +$71.4K 0.53% 77
2019
Q3 		$2.23M Buy
+29,866
New +$2.39M 0.59% 66

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Moody Aldrich Partners's NVCR Position: Q2 2020 in Review

Moody Aldrich Partners sold out of NovoCure (NVCR) in Q2 2020, closing a stake of 30,682 shares — an estimated $2.07M sold.

Moody Aldrich Partners first reported a position in NVCR in Q3 2019 and held it in 3 quarters. The position peaked at $2.59M in Q4 2019. 264 funds tracked by Wall St. Rank hold NVCR as of Q2 2020.

  • Moody Aldrich Partners reported no remaining NovoCure position as of Q2 2020 after selling out during the quarter.
  • Moody Aldrich Partners sold 30,682 NovoCure shares in Q2 2020, an estimated $2.07M.
  • Moody Aldrich Partners first reported a position in NovoCure in Q3 2019 and held it in 3 quarters.
  • Moody Aldrich Partners's NovoCure position peaked at $2.59M in Q4 2019.
  • 264 funds tracked by Wall St. Rank held NovoCure as of Q2 2020.

Based on Moody Aldrich Partners's 13F filing for Q2 2020, filed 30 Jul 2020.